Cell death pathologies: targeting death pathways and the immune system for cancer therapy

Francesca Pentimalli, Sandro Grelli, Nicola Di Daniele, Gerry Melino, Ivano Amelio

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Alterations in the molecular mechanisms of cell death are a common feature of cancer. These alterations enable malignant cells to survive intrinsic death signalling leading to accumulation of genetic aberrations and helping them to cope with adverse conditions. Regulated cell death has historically been exclusively associated with classical apoptosis; however, increasing evidence indicates that several alternative mechanisms orchestrate multiple death pathways, such as ferroptosis, entosis, necroptosis and immunogenic cell death, each with distinct underlying molecular mechanisms. Although pharmacological targeting of cell death pathways has been the subject of intensive efforts in recent decades with a dominant focus on targeting apoptosis, the identification of these novel death pathways has opened additional venues for intervention in cancer cells and the immune system. In this mini-review, we cover some recent progress on major recently emerged cell death modalities, emphasizing their potential clinical and therapeutic implications. We also discuss the interplay between cell death and immune response, highlighting the potential of the combination of traditional anticancer therapy and immunocheckpoint blockade. While attempting to stimulate discussion and draw attention to the possible clinical impact of these more recently emerged cell death modalities, we also cover the major progress achieved in translating strategies for manipulation of apoptotic pathways into the clinic, focusing on the attempts to target the anti-apoptotic protein BCL2 and the tumour suppressor p53.

Original languageEnglish
Pages (from-to)539-554
Number of pages16
JournalGenes and Immunity
Volume20
Issue number7
DOIs
Publication statusPublished - Sep 1 2019

Fingerprint

Immune System
Cell Death
Pathology
Neoplasms
Entosis
Therapeutics
Apoptosis
Apoptosis Regulatory Proteins
Pharmacology

ASJC Scopus subject areas

  • Immunology
  • Genetics
  • Genetics(clinical)

Cite this

Cell death pathologies : targeting death pathways and the immune system for cancer therapy. / Pentimalli, Francesca; Grelli, Sandro; Di Daniele, Nicola; Melino, Gerry; Amelio, Ivano.

In: Genes and Immunity, Vol. 20, No. 7, 01.09.2019, p. 539-554.

Research output: Contribution to journalReview article

Pentimalli, F, Grelli, S, Di Daniele, N, Melino, G & Amelio, I 2019, 'Cell death pathologies: targeting death pathways and the immune system for cancer therapy', Genes and Immunity, vol. 20, no. 7, pp. 539-554. https://doi.org/10.1038/s41435-018-0052-x
Pentimalli, Francesca ; Grelli, Sandro ; Di Daniele, Nicola ; Melino, Gerry ; Amelio, Ivano. / Cell death pathologies : targeting death pathways and the immune system for cancer therapy. In: Genes and Immunity. 2019 ; Vol. 20, No. 7. pp. 539-554.
@article{d57d1d4e1fa7493fa162c25fd371e67a,
title = "Cell death pathologies: targeting death pathways and the immune system for cancer therapy",
abstract = "Alterations in the molecular mechanisms of cell death are a common feature of cancer. These alterations enable malignant cells to survive intrinsic death signalling leading to accumulation of genetic aberrations and helping them to cope with adverse conditions. Regulated cell death has historically been exclusively associated with classical apoptosis; however, increasing evidence indicates that several alternative mechanisms orchestrate multiple death pathways, such as ferroptosis, entosis, necroptosis and immunogenic cell death, each with distinct underlying molecular mechanisms. Although pharmacological targeting of cell death pathways has been the subject of intensive efforts in recent decades with a dominant focus on targeting apoptosis, the identification of these novel death pathways has opened additional venues for intervention in cancer cells and the immune system. In this mini-review, we cover some recent progress on major recently emerged cell death modalities, emphasizing their potential clinical and therapeutic implications. We also discuss the interplay between cell death and immune response, highlighting the potential of the combination of traditional anticancer therapy and immunocheckpoint blockade. While attempting to stimulate discussion and draw attention to the possible clinical impact of these more recently emerged cell death modalities, we also cover the major progress achieved in translating strategies for manipulation of apoptotic pathways into the clinic, focusing on the attempts to target the anti-apoptotic protein BCL2 and the tumour suppressor p53.",
author = "Francesca Pentimalli and Sandro Grelli and {Di Daniele}, Nicola and Gerry Melino and Ivano Amelio",
year = "2019",
month = "9",
day = "1",
doi = "10.1038/s41435-018-0052-x",
language = "English",
volume = "20",
pages = "539--554",
journal = "Genes and Immunity",
issn = "1466-4879",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Cell death pathologies

T2 - targeting death pathways and the immune system for cancer therapy

AU - Pentimalli, Francesca

AU - Grelli, Sandro

AU - Di Daniele, Nicola

AU - Melino, Gerry

AU - Amelio, Ivano

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Alterations in the molecular mechanisms of cell death are a common feature of cancer. These alterations enable malignant cells to survive intrinsic death signalling leading to accumulation of genetic aberrations and helping them to cope with adverse conditions. Regulated cell death has historically been exclusively associated with classical apoptosis; however, increasing evidence indicates that several alternative mechanisms orchestrate multiple death pathways, such as ferroptosis, entosis, necroptosis and immunogenic cell death, each with distinct underlying molecular mechanisms. Although pharmacological targeting of cell death pathways has been the subject of intensive efforts in recent decades with a dominant focus on targeting apoptosis, the identification of these novel death pathways has opened additional venues for intervention in cancer cells and the immune system. In this mini-review, we cover some recent progress on major recently emerged cell death modalities, emphasizing their potential clinical and therapeutic implications. We also discuss the interplay between cell death and immune response, highlighting the potential of the combination of traditional anticancer therapy and immunocheckpoint blockade. While attempting to stimulate discussion and draw attention to the possible clinical impact of these more recently emerged cell death modalities, we also cover the major progress achieved in translating strategies for manipulation of apoptotic pathways into the clinic, focusing on the attempts to target the anti-apoptotic protein BCL2 and the tumour suppressor p53.

AB - Alterations in the molecular mechanisms of cell death are a common feature of cancer. These alterations enable malignant cells to survive intrinsic death signalling leading to accumulation of genetic aberrations and helping them to cope with adverse conditions. Regulated cell death has historically been exclusively associated with classical apoptosis; however, increasing evidence indicates that several alternative mechanisms orchestrate multiple death pathways, such as ferroptosis, entosis, necroptosis and immunogenic cell death, each with distinct underlying molecular mechanisms. Although pharmacological targeting of cell death pathways has been the subject of intensive efforts in recent decades with a dominant focus on targeting apoptosis, the identification of these novel death pathways has opened additional venues for intervention in cancer cells and the immune system. In this mini-review, we cover some recent progress on major recently emerged cell death modalities, emphasizing their potential clinical and therapeutic implications. We also discuss the interplay between cell death and immune response, highlighting the potential of the combination of traditional anticancer therapy and immunocheckpoint blockade. While attempting to stimulate discussion and draw attention to the possible clinical impact of these more recently emerged cell death modalities, we also cover the major progress achieved in translating strategies for manipulation of apoptotic pathways into the clinic, focusing on the attempts to target the anti-apoptotic protein BCL2 and the tumour suppressor p53.

UR - http://www.scopus.com/inward/record.url?scp=85058853093&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058853093&partnerID=8YFLogxK

U2 - 10.1038/s41435-018-0052-x

DO - 10.1038/s41435-018-0052-x

M3 - Review article

C2 - 30563970

AN - SCOPUS:85058853093

VL - 20

SP - 539

EP - 554

JO - Genes and Immunity

JF - Genes and Immunity

SN - 1466-4879

IS - 7

ER -